N^α-(tert-butoxycarbonyl)glycine 9-fluorenylmethyl ester | 124927-97-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: N^α-(tert-butoxycarbonyl)glycine 9-fluorenylmethyl ester
• 英文别名: Boc-GlyOFm；N-[(1,1-dimethylethoxy)carbonyl]glycine 9H-fluoren-9-ylmethyl ester；9H-fluoren-9-ylmethyl 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetate
• CAS: 124927-97-5
• 化学式: C₂₁H₂₃NO₄
• 分子量: 353.418
• InChiKey: NKQLSCJUJKKBRS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N^α-(tert-butoxycarbonyl)glycine 9-fluorenylmethyl ester 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.5h， 以77%的产率得到glycine 9-fluorenylmethyl ester
  参考文献：
  名称：

  4-(9-Fluorenylmethyloxycarbonyl)phenylhydrazine (FmPH):  A New Chromophoric Reagent for Quantitative Monitoring of Solid-Phase Aldehydes^1-3

  摘要：

  A direct method for quantifying solid-phase aldehydes has been developed, using a new reagent, 4-(9-fluorenylmethyloxycarbonyl)phenylhydrazine (FmPH). The FmPH reagent was synthesized in three steps (24% overall yield) from commercially available p-hydrazinobenzoic acid. Resin-bound aldehydes reacted quantitatively with FmPH, in the presence of trimethylorthoformate (TMOF) as a dehydrating agent, to form a highly conjugated, immobilized FmPH-hydrazone. Next, mild treatment of the hydrazone with an excess of piperidine-N,N-dimethylformamide (1:1) released the piperidine-dibenzofulvene adduct chromophore (epsilon(301nm) = 7800 M-1 cm(-1)) from the support. FmPH quantitation of aldehydes proved to be a straightforward, sensitive, and reproducible technique for monitoring resin-bound aldehydes [albeit insufficiently reactive to allow reliable quantification of ketones]. The FmPH aldehyde assay is applicable to a range of solid supports, as demonstrated specifically for poly(ethylene glycol)-polystyrene (PEG-PS), aminomethylpolystyrene (AMP), and cross-linked ethoxylate acrylate resin (CLEAR).

  DOI：

  10.1021/jo049830b
• 作为产物：
  描述：

  9-芴甲醇 生成 N^α-(tert-butoxycarbonyl)glycine 9-fluorenylmethyl ester
  参考文献：
  名称：

  GUNNARSSON, KESTIN;RAGNARSSON, ULF, ACTA CHEM. SCAND., 44,(1990) N, C. 944-951

  摘要：

  DOI：

文献信息

• Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
  申请人：Ardelyx, Inc.

  公开号：US10392413B2

  公开（公告）日：2019-08-27

  The invention relates to non-systemic TGR5 agonist useful in the treatment of chemotherapy-induced diarrhea, diabetes, Type II diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during short bowel syndrome, and irritable bowel syndrome (IBS), and other TGR5 associated diseases and disorders, having the Formula: where R1, R2, R2′, R3, R4, X1, X2, X3, X4, Q, and n are described herein.

  本发明涉及可用于治疗化疗引起的腹泻、糖尿病、II 型糖尿病、妊娠糖尿病、空腹血糖受损、糖耐量受损、胰岛素抵抗、高血糖、肥胖、代谢综合征、溃疡性结肠炎、克罗恩病、肠外营养相关疾病，尤其是短肠综合征和肠易激综合征（IBS），以及其他与 TGR5 相关的疾病和失调的非系统性 TGR5 激动剂，其配方如下： 其中 R1、R2、R2′、R3、R4、X1、X2、X3、X4、Q 和 n 如本文所述。
• Gunnarsson, Kerstin; Ragnarsson, Ulf, Acta Chemica Scandinavica, 1990, vol. 44, # 7, p. 944 - 951
  作者：Gunnarsson, Kerstin、Ragnarsson, Ulf

  DOI：——

  日期：——
• SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS
  申请人：Ardelyx, Inc.

  公开号：EP3390382A1

  公开（公告）日：2018-10-24
• [EN] SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS<br/>[FR] UTILISATION DE COMPOSÉS 4-PHÉNYL PYRIDINE SUBSTITUÉS EN TANT QU'AGONISTES NON SYSTÉMIQUES DU TGR5
  申请人：ARDELYX INC

  公开号：WO2017106818A1

  公开（公告）日：2017-06-22

  The invention relates to non-systemic TGR5 agonist useful in the treatment of chemotherapy-induced diarrhea, diabetes, Type II diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during short bowel syndrome, and irritable bowel syndrome (IBS), and other TGR5 associated diseases and disorders, having the Formula: (I'), where R1, R2, R2', R3, R4, X1, X2, X3, X4, Q, and n are described herein.